How long should we allow metformin to remain the bogeyman in CKD? Should MALA scare us from ever letting our patients benefit from metformin? Join us as we discuss some rare prospective data on metformin in moderate to severe CKD.
Background
This week, we will discuss the 2024 KDIGO Guidelines on CKD, part 1. In this section we will discuss the first two chapters on CKD evaluation and risk stratification. Let’s dive in!
Background
This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.
Background
This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
Background
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
